Season 2 Episode 177
In this episode of The Swine Health Blackbelt Podcast, Dr. Troy Kaiser from Boehringer Ingelheim shares the latest on PCV2 immunization innovation and how shifting genotypes influence swine health protocols. He details safety and efficacy trials, label claims, and what this means for herd-level protection. Learn whatโs next in immunization strategy and how to optimize immunity. Listen now on all major platforms!
"Even without overt clinical signs, PCV2 can still impact growth, performance, efficiency, and herd consistency."
๐ ๐ฒ๐ฒ๐ ๐๐ต๐ฒ ๐ด๐๐ฒ๐๐: Dr. Troy Kaiser is a Principal Scientist and Clinical Project Lead & Laboratory Study Lead for livestock immunizers at Boehringer Ingelheim Animal Health, leading clinical studies for swine immunizer development. He earned his B.S. and M.S. from South Dakota State University, followed by his DVM. from Iowa State University. With decades of experience in swine virology, his work focuses on advancing the efficacy and safety of immunizers for PCV2.
Liked this one? Donโt stop now โ Hereโs what we think youโll love!
Dr. Pablo Piรฑeyro: PCV4 & Co-infections | Ep. 139
Dr. Tyler Bauman: PRRS Control in Grow-Finish Pigs | Ep. 156
What you will learn:
The Swine Health Blackbelt Podcast is trusted and supported by innovative companies like:
- Elanco
๐๐ถ๐๐๐ฒ๐ป ๐ผ๐ป ๐๐ฝ๐ฝ๐น๐ฒ ๐ฃ๐ผ๐ฑ๐ฐ๐ฎ๐๐๐, ๐ฆ๐ฝ๐ผ๐๐ถ๐ณ๐ ๐ผ๐ฟ ๐ฎ๐ป๐ ๐บ๐ฎ๐ท๐ผ๐ฟ ๐ฝ๐น๐ฎ๐๐ณ๐ผ๐ฟ๐บ.
Website:ย The Swine Health Blackbelt Podcast
Instagram:ย Swine Campus
LinkedIn:ย Swine Campus
Published on 1ย month ago
If you like Podbriefly.com, please consider donating to support the ongoing development.
Donate